Review

Marine-Derived Compounds for the Potential Treatment of Glucocorticoid Resistance in Severe Asthma

Cristina Mihaela Ghiciuc 1,*,†, Andrei Gheorghe Vicovan 1,*,†, Celina Silvia Stafie 2,†, Sabina Antonela Antoniu 3,† and Paraschiva Postolache 4,†

1 Department of Morpho-Functional Sciences II—Pharmacology and Clinical Pharmacology, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy of Iasi, 16 Universitatii Street, 700115 Iasi, Romania
2 Department of Preventive Medicine and Interdisciplinarity—Family Medicine Discipline, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy of Iasi, 16 Universitatii Street, 700115 Iasi, Romania; celina.stafie@umfiasi.ro
3 Department of Medicine II—Palliative Care Nursing, Grigore T. Popa University of Medicine and Pharmacy of Iasi, 16 Universitatii Street, 700115 Iasi, Romania; sabina.antoniu@umfiasi.ro
4 Department of Medicine I—Pulmonary Rehabilitation Clinic, Grigore T. Popa University of Medicine and Pharmacy of Iasi, 16 Universitatii Street, 700115 Iasi, Romania; paraschiva.postolache@umfiasi.ro
* Correspondence: cristina.ghiciuc@umfiasi.ro (C.M.G.); andrei.vicovan@email.umfiasi.ro (A.G.V.)
† These authors contributed equally to this work.

Abstract: One of the challenges to the management of severe asthma is the poor therapeutic response to treatment with glucocorticosteroids. Compounds derived from marine sources have received increasing interest in recent years due to their prominent biologically active properties for biomedical applications, as well as their sustainability and safety for drug development. Based on the pathobiological features associated with glucocorticoid resistance in severe asthma, many studies have already described many glucocorticoid resistance mechanisms as potential therapeutic targets. On the other hand, in the last decade, many studies described the potentially anti-inflammatory effects of marine-derived biologically active compounds. Analyzing the underlying anti-inflammatory mechanisms of action for these marine-derived biologically active compounds, we observed some of the targeted pathogenic molecular mechanisms similar to those described in glucocorticoid (GC) resistant asthma. This article gathers the marine-derived compounds targeting pathogenic molecular mechanism involved in GC resistant asthma and provides a basis for the development of effective marine-derived drugs.

Keywords: marine-derived compounds; glucocorticoid-resistant; severe asthma; drug development; biomedical applications

1. Introduction

Asthma is a chronic inflammatory disease of the lower airways characterized by airway hyperresponsiveness and remodeling, leading to wheeze, cough, chest tightness, and difficulty in breathing. The prevalence of asthma is still increasing, while the potential risk factors for asthma seems to make equal contributions [1]. Although among the population of adults with asthma only 3% to 10% are classified as suffering from severe asthma [2,3], the costs of healthcare per patient are higher than those for stroke, type 2 diabetes, or chronic obstructive pulmonary disease (COPD) [4]. According to the current guidelines [5], difficult-to-control asthma is asthma that is uncontrolled despite treatment with high-dose inhaled glucocorticoids (ICS) combined with long-acting β2-agonists or other controllers, or that requires such treatment to maintain good symptom control and reduce exacerbation; severe asthma is considered a subset of difficult-to-control asthma that is uncontrolled despite adherence to maximal optimized Step 4 or Step 5 therapy and treatment of contributory factors, or that worsens when high-dose treatment is reduced.
Glucocorticoid resistance in the main challenge of severe asthma. A common feature of patients with severe asthma is their poor response to high doses of ICS and then systemic glucocorticoids (GCs). This inadequate response is called steroid-unresponsive or GC resistance. These patients, however, may respond well to β2-adrenergic agonist-mediated vasodilation; but if after 2 weeks of appropriate-dose steroid treatment the improvements in forced expiratory volume in 1 s (FEV1) are <15%, then the asthma is defined as GC resistant [6–8].

Compounds derived from marine sources have received increasing interest in recent years due to their prominent biologically active properties for biomedical applications, and to their being a new and safe source for drug development [9–13]. New compounds were recently reviewed and proposed as potential treatments for different diseases, such as cancer [14], cardiovascular diseases [15], rheumatoid arthritis [16], neurological diseases [17], and others.

Many marine-derived biologically active compounds target pathogenic molecular mechanisms common to those described in GC-resistant asthma; therefore, we sought in this review to gather the marine-derived compounds targeting the pathogenic molecular mechanism involved in GC resistant asthma and to provide a basis for the development of effective marine-derived drugs.

2. Pathobiological Features Associated with Glucocorticoid Resistance

In practice, the diagnosis of GC resistance in asthma is based on the clinical history and evaluation of respiratory function after sufficient steroid treatments. Often, patients receive increasing doses of steroids for extended periods, until it is recognized that this is ineffective for treating their severity of asthma. The toxic side effects of long-term high-dose steroids are well known for increasing susceptibility to infections, cardiovascular disease, hyperglycemia, and osteoporosis. Although there are currently no clinically accepted biomarkers or phenotypes for resistance, some studies identified asthma phenotypes associated with GC resistance [5,18,19], as depicted in Table 1.

Table 1. Degree of Glucocorticoid Resistance and Corresponding Asthma Phenotypes.

| Degree of Glucocorticoid Resistance | Asthma Phenotypes                        | Pathobiologic Features                  |
|------------------------------------|------------------------------------------|-----------------------------------------|
| Severe corticosteroid resistance   | Obesity-related asthma                    | Absence of Th2 specific response        |
|                                    |                                          | Increased oxidative stress              |
|                                    | Neutrophilic asthma                       | Increased Th-17 response (increased IL-8, neutrophilia) |
|                                    | Late-onset eosinophilic asthma            | Increased IL-5                          |
|                                    |                                          | Eosinophilia                            |
| Moderate corticosteroid resistance | Early-onset allergic asthma               | Increased Th2 specific response         |
|                                    |                                          | Presence of antigen-specific IgE       |
|                                    | Exercise-induced asthma                   | Increased Th2 specific response         |
|                                    |                                          | Increased mast cells degranulation      |
|                                    |                                          | Increased CysLTs                        |

Th, T helper lymphocyte; Ig, Immunoglobuline; IL, interleukin; CysLTs, cysteinyl leukotrienes.

3. Mechanisms of Glucocorticoid Resistance as Potential Therapeutic Targets

3.1. Mechanisms of Action of Glucocorticoids

Although the topic has been extensively reviewed by Keenan et al. [20] and many others [7,21–23], before delving into the altered cellular and molecular basis of signaling that leads to GCs resistance, it is important to review the heterogenous mechanisms of action by which GCs exert their downstream effect.

GCs have been extensively used in many diseases for a long time, but their molecular mechanisms of action are still not completely understood. GCs bind on the intracellular
glucocorticoid receptors (GRs) of the target cell. There are two major variants of GRs
with different C-terminal domains: GR-α, and GR-β. GR-α isoform-bind to GCs and
affect GR signaling pathways through various post-translational modifications, such as
phosphorylation, acetylation, and other modifications [24], while GR-β is unable to bind
to GCs and cannot affect GC-induced modification. GR-β probably regulates GC activity,
antagonizes GR-α isoform, and regulates GR-α/β heterodimers [25,26].

Genomic mechanisms are mediated by binding to GRs in the cytoplasm and further
translocation of the GC/GR complex into the nucleus, while non-genomic mechanisms are
mediated through specific interaction with GRs, or nonspecific interactions with the cell
membrane [27]. Intracytoplasmic GRs present in inactive forms, in a protein complex, and
attached to a chaperone protein. The dissociation of GR and the dissociation of chaperone
protein upon activation allow the translocation of GR into the nucleus [28]. Inside the
nucleus, the GC/GR complex regulates up to 20% of genes expressed by immune cells by
trans-repressing inflammatory genes and stimulating the transcription of anti-inflammatory
genes, leading to the reduced activation, recruitment, and survival of inflammatory and
epithelial cells [29–31]; it also regulates mRNA stability [32] and the immunomodulatory
function of smooth muscle cells and airway remodeling in asthma [33].

High concentrations of GCs exert non-genomic actions; inhibit the degranulation of
mast cells through the stabilization of the plasma membrane or through a reduction in
[Ca2+] elevation [34]; and promote anti-inflammatory effects through negative interference
with MAPK signaling pathways [35].

3.2. Glucocorticoids Resistance: Cellular and Molecular Basis

Decreased GC responsiveness can be inherited or acquired. In the case of inherited
decreased GC responsiveness, GC insensitivity most probably is not caused by a singular
genetic mutation and involves a range of genetic variations. Some of the involved genes
have already been determined [36–38] and are not the aim of our study.

The research into specific studies dedicated to GC resistance revealed the following
responsible mechanisms:

- Deficient binding between the GC and the GR or between the GR complex and DNA
  may be a cause [39].
- Increased antagonism is determined either by increased GR-β expression [40] or by
diminished GR-α expression [41]. This can be explained by the IL-2/IL-4-induced
  suppression of GR-α (and not GR-β) expression in peripheral blood mononuclear
  cells (PBMCs) [42]. Additionally, IL-2 and IL-4 can synergistically reduce (via the
  p38MAPK pathway) nuclear translocation and binding affinity in T-cells (reversible
  by a p38 inhibitor) [43]. Furthermore, IL-17 and IL-23 cytokines were reported to
  significantly upregulate GR-β [42].
- Inflammation or oxidative stress has the potential to negatively affect GC signaling [22].
- The expression of various anti-inflammatory genes induced by GCs can be reduced
  through GR phosphorylation by, for example, p38 mitogen-activated protein kinase
  (MAPK) and by the reduced activity of histone deacetylase 2 (HDAC2) [43,44].
- The upregulation of certain cytokines, such as IL-2, IL-4, and IL-13, was detected in
  the lungs of patients with GC unresponsiveness [45–47]; in vitro, the overexpression
  of these cytokines was associated with the phosphorylation of GR and a decrease in
  nuclear translocation in inflammatory cells through the activation of p38 mitogen-
  activated protein kinase [48]. p38MAPK activity was demonstrated to be higher in
  alveolar macrophages from patients with impaired response to GCs compared to
  ‘responders’. Furthermore, the expression of MKP-1 (DUSP1 gene), an endogenous
  inhibitor of the MAPK pathway, was significantly diminished in alveolar macrophages
  after GCS exposure, leading to an increase in p38MAPK activity [49]. Furthermore,
  p38MAPK inhibitors, such as AZD7624 or SB203580, have recently been investigated
  in corticosteroid-resistant asthmatic populations [50,51].
Increased HDAC activity using theophylline, PI3K, and p38 MAPK inhibitors demonstrated beneficial effects [52–54], especially in glucocorticoid-resistant asthmatic smokers, where increased antagonism of the GR-α resulted from a reduced ratio of GR-α to GR-β isoforms [55]. Moreover, reduced total HDAC activity in PBMCs isolated from prednisone-dependent asthmatics compared to ICS-maintained moderate asthmatics and healthy volunteers was reported [56].

GC resistance has been associated with *Haemophilus influenzae*, *Chlamydia pneumoniae*, *Influenza A virus* (IAV), rhinovirus, and *Respiratory syncytial virus* (RSV) infections [57–61]. The molecular mechanism proposed for glucocorticoid insensitivity in rhinovirus-infected primary human bronchial epithelial cells is the activation of NF-κB and c-Jun N-terminal kinase, which leads to a decrease in GR-α nuclear translocation [62]. The influence of NF-κB activity on GC resistance has also been confirmed by research on the blockade of this pathway [63,64].

Using mouse models of steroid-resistant asthma driven by bacterial (*Chlamydia* and *Haemophilus influenzae*) and viral (influenza and RSV) respiratory tract infections, Kim et al. demonstrated that steroid insensitivity can be induced through PI3K-mediated phosphorylation and the nuclear translocation of pAKT [65].

By upregulating miR-9 expression in pulmonary macrophages, IFN-γ can increase GR phosphorylation and, consequently, inhibit GR nuclear translocation in experimental models of steroid-resistant airway hyperresponsiveness [66].

In a study of human fetal airway smooth muscle cells, TNF-α and IFN-γ cytokines were shown to sustain GC resistance by promoting the Nuclear factor-κB (NF-κB) pathway and Stat1 phosphorylation [67]. TNF-α also demonstrated the potential to activate the c-Jun N-terminal kinase (JNK), which directly phosphorylated GR-α at Ser226 and inhibited GRE-binding [68].

The nitrosylation of the glucocorticoid receptor at the HSP90 (chaperone) binding site can be caused by high levels of nitric oxide generated in situ as a result of eosinophilic inflammation. This can decrease its affinity with chaperone proteins that protect it from cytoplasmic degradation. The binding affinity to GCs (ligand) in structural cells, such as fibroblasts, can also be reduced by nitrosylation [69]. In conclusion, asthmatics with persistent airway eosinophilia with increased localized nitric oxide production and possibly increased remodeling may develop GC resistance through the repeated nitrosylation of GR.

Increased NLR Family Pyrin Domain Containing 3 (NLRP3) inflammasome/IL-1β activation contributed to glucocorticoid resistance in murine models of steroid-resistant allergic airway disease [70].

The Th2 cytokines IL-13 and IL-5 each possess the ability to induce diminished GR-binding affinity. The effect of hydrocortisone in suppressing LPS-induced IL-6 production by monocytes was demonstrated to be significantly hindered when the cells were primed by IL-13 [71]. Additionally, IL-5-primed eosinophils were unresponsive to GS-induced apoptosis (via synergistic upregulation of nuclear-factor IL-3 due to a cross-talk between GCS-induced trans-activation signaling and IL-5 antiapoptotic pathway) [72].

The adoptive transfer of Th17 cells in mice resulted in the development of steroid insensitivity, and Th17 cells and IL-17A levels are frequently associated with GC resistance in asthmatic patients [73–75]. Accordingly, the expression of GR-β has been reported to increase Th17 responses [76]. In the obesity phenotype of asthma, the associated steroid resistance may be induced by IL-17 produced by the pulmonary type 3 innate lymphoid cells [77]. The role of IL-7 in GC resistance has been confirmed by the augmentation of dexamethasone anti-inflammatory action in diesel exhaust particle-induced neutrophilic steroid insensitivity secondary to anti-IL-17 therapy [78].

Bhavsar et al. showed that dexamethasone could not suppress the lipopolysaccharide (LPS)-induced release of pro-inflammatory cytokines [49]. This finding was supported by Li et al., who simulated an airway infection in a mouse model of steroid-resistant...
asthma through the concomitant administration of LPS + IFN-γ; consequently, PP2A activity (that induced JNK) was attenuated and led to the phosphorylation of GR-α at Ser226, thereby hindering glucocorticoid receptor nuclear translocation in pulmonary macrophages [66].

- LPS promoted a shift from Th2-derived airway eosinophilic inflammation to Th17-driven neutrophilic inflammation in an ovalbumin-sensitized murine asthma model [79].
- Dysregulated IL-10 production is associated with GC insensitivity. This is probably due to impaired IL-10 production, according to Hawrylowicz et al., who compared in vitro stimulated T lymphocytes from corticosteroid-resistant asthmatic with dexamethasone to T lymphocytes from steroid-sensitive asthmatics [80].
- The induction of Th2/Th17 responses in fungus-exposed patients has the potential to develop GC resistance [65]. More precisely, in neonatal mice, *Aspergillus alternata* exposure induced IL-33 dependent GC resistant asthma, mediated by ILC2 and Th2 cells [81]. The suggested mechanism underlying glucocorticoid insensitivity is the activation of p38-MAPK in CD4 + T cells and induction of phosphorylation of GR by IL-33 [82].

GCs also produce pro-inflammatory effects under stress conditions [83]. Table 2 depicts the potential targeted molecular and immunopathogenic mechanisms in glucocorticoid-resistant severe asthma.

| Molecular Targets | Pharmacological Effect | References |
|-------------------|------------------------|------------|
| Decrease in activity of MAPK | Decrease in GR phosphorylation | [43, 44, 48–55] |
|                    | Increased ratio of GR-α to GR-β isoforms | |
| Increase of activity of HDAC | Decrease in GR phosphorylation | [43, 44, 52–54, 56] |
|                    | Increased ratio of GR-α to GR-β isoforms | |
| Decrease in activation of JNK | Decrease in GR phosphorylation | [68] |
|                    | Increase in GR-α nuclear translocation | [62] |
| Nitric oxide decrease | Decrease in nitrosylation of GR at HSP90 (chaperone binding site) | [69, 84] |
| Decrease in oxidative stress | Decrease in nitrosylation of GR at HSP90 (chaperone binding site) | [69, 84] |
| Downregulation of Th2 | Increase in GR-α expression and nuclear translocation | [40–43, 45–48] |
| IL-4 | Increase in GR binding affinity in T-cells | |
| IL-5 | Decrease in GR phosphorylation | |
| IL-13 | Decrease in GR binding affinity | [45–48] |
| Downregulation of non-Th2 | Decrease in GR-β expression | [42, 76, 77] |
| IL-17 | Decrease in GR-β expression | [42] |
| IL-23 | Decrease in GR-β expression | [42] |
| IFN-γ | Decreased GR phosphorylation and stimulation of GR nuclear translocation | [66] |
|                    | Increase in GR-α nuclear translocation (through downregulation of NFκB) | [67] |
| TNF-α | Increase in GR-α nuclear translocation (through downregulation of NFκB) | [67] |
|                    | Decrease in GR-α phosphorylation at Ser226 and the inhibition of GRE-binding (through downregulation of JNK) | [68] |
### Table 2. Cont.

| Molecular Targets | Pharmacological Effect | References |
|------------------|------------------------|------------|
| IL-33            | Decreased GR phosphorylation | [81,82]    |
| IL-1β            | Unknown                | [70]       |

Inhibition of inflammatory response shift: Th2 to Th17

- Decreased GR phosphorylation and stimulate GR nuclear translocation
- Increase in GR-α nuclear translocation (through downregulation of NF-κB)
- Decrease in GR-α phosphorylation at Ser226 and the inhibition of GRE-binding (through downregulation of JNK)

MAPK, Mitogen-activated protein kinase; GR, glucocorticoid receptor; HDAC, histone deacetylase; JNK, c-Jun N-terminal kinase; HSP90, heat shock protein; NF-κB, Nuclear factor-κB; †, inhibition of inflammatory response shift from Th2-derived airway eosinophilic inflammation to Th17-driven neutrophilic inflammation (through inhibition of LPS-induced release of pro-inflammatory cytokines).

### 4. Potentially Therapeutic Effect of Marine-Derived Biologically Active Compounds in Severe Asthma

Experimental studies with marine compounds demonstrating their effectiveness in vitro or in vivo models of bronchial asthma are scarce [84–88]. On the other hand, recent studies revealed the significant potential of marine compounds to interfere with molecular mechanisms similar to those involved in GC-resistant asthma. Therefore, a standardized inclusion–exclusion criterion was implemented, aiming to justify the current review. The literature search queries were performed until September, 2021. We included and analyzed all the original articles from PubMed and Scopus databases, with marine compounds that potentially target these molecular mechanisms; we excluded reviews and generalized or irrelevant studies (results illustrated in Table 3).

Some of these compounds from different marine sources are well characterized and have well-defined structures (Table 4), while others are extracts with complex compositions.

#### 4.1. Cellular Signal/Corticoresistance

Fucosterol, a phytosterol from the marine brown algae Padina boryana, demonstrated anti-inflammatory effects through its dose-dependent downregulation of pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α) and of the Nrf2/HO-1 pathway [89].

Mojabanchromanol (MC), a chromanol isolated from the brown algae Sargassum horneri, demonstrated anti-oxidant effects through the attenuation of particulate matter-induced oxidative stress, the reduction of the ROS-mediated phosphorylation of MAPK extracellular signal-regulated kinase 1/2 (Erk1/2) and of c-JNK, and the inhibition of the secretion of pro-inflammatory cytokines (IL-6, IL-1β and IL-33). The authors proposed that mojabanchromanol be developed as a therapeutic agent against particulate matter-induced airway inflammatory responses [84].

Sargachromenol, isolated from Sargassum horneri, demonstrated anti-inflammatory effects in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages, by reducing the nitric oxide (NO); and in intracellular reactive oxygen species (ROS), by decreasing the mRNA expression levels of inflammatory cytokines (IL-1β, IL-6, and TNF-α) and by inhibiting the activation of NFκB and MAPK signaling [90].
### Table 3. Potential targeted mechanisms in glucocorticoid-resistant severe asthma.

| Compound | Specie | Origin | Class | Molecular Targets | References |
|----------|--------|--------|-------|-------------------|------------|
| **Simple compounds** | | | | **Downregulation of Th2** | **Downregulation of Non-Th2** | **References** |
| Fucosterol | Padina boryana | brown algae | phytosterol | x | x | x | x | [89] |
| Mojabanchromanol | Sargassum horneri | brown algae | chromanol | x | x | | x | [84] |
| Sargachromenol | Sargassum horneri | brown algae | chromenol | x | x | | x | [90] |
| Fucoidan | Saccharina japonica | brown algae | polysaccharides | x | x | x | x | [91] |
| 3,4,5,5-Tetramethyl-4-(3′-oxopentyl)-2-cyclohexen-1-one | Ulva fasciata Deliles | green algae | sesquiterpenoids | | | x | | [92,93] |
| 4-hydroxy-2,3-dimethyl-2-nonen-4-olide | Ulva pertusa | green algae | extract | | | x | | [94] |
| (E)-9-Oxoocadec-10-enoi-acid and (E)-10-Oxoocadec-8-enoi-acid | Gracilaria verrucosa | red algae | fatty acids | x | x | | x | [95] |
| Cyclo(L-Pro-D-Val), cyclo(L-Pro-L-Tyr), cyclo(L-Pro-D-Leu) | Bacillus sp. HC001, Piscicoccus sp. 12L081 | bacteria | diketopiperazine | x | x | | x | [96] |
Table 3. Cont.

| Compound                        | Specie                                      | Origin              | Class               | Molecular Targets                                                                 | References |
|---------------------------------|---------------------------------------------|---------------------|---------------------|----------------------------------------------------------------------------------|------------|
|                                 |                                             |                     |                     | Downregulation of Th2 | Downregulation of Non-Th2 | Inhibition of Inflammatory Response Shift: Th2 to Th17 |
| Cycloprodigiosin                | *Pseudoalteromonas denticficans*            | bacteria            | prodigiosin         | x | x |                  |
| C-Phycocyanin                   | *Nostoc Muscorum Cyanobacteria*             | bacteria            | Polypeptide         | x | |                  |
| Phenazines 1,2                  | *Streptomyces sp.*                          | bacteria            | aromatic secondary metabolites | x | x | x |
| Griseusrazin A                  | *Streptomyces griseus*                      | bacteria            | pyrazine-type molecules | x | x | x |
| Grassystatin A                  | *Lyngbya confervoides*                     | bacteria            | linear decadepsipeptide | x | | |
| Ogipeptins A-D                  | *Pseudoalteromonas sp.* 71903               | bacteria            | cyclic peptides     | x | x | x |
| Pyrenocine A                    | *Penicillium paxilli*                       | fungus              | phytotoxins         | x | | |
| (−)-1S-myrothecol and (+)-1R-myrothecol | *Myrothecium sp.* BZO-L062               | fungus              | alkylresorcinol     | x | | |
| Chrysamides A–C                 | *Penicillium chrysogenum* SCS041001         | fungus              | dimeric nitrophenyl trans-epoxyamides | x | | |
| Brevicompanine E                | *Penicillium sp.*                           | fungus              | diketopiperazine derivatives | x | x | x |
Table 3. Cont.

| Compound | Specie | Origin | Class | Molecular Targets | References |
|----------|--------|--------|-------|-------------------|------------|
| Polyoxygenated Sterols & bolinaquinone | *Dysidea sp.* | fungus | sterols | Downregulation of MAPK | x | [112,113] |
| Hirsutanol A | *Chondrostereum sp.* NTOU14196 | fungus | Sesquiterpene compound | Increase of Activity of HDAC | x | x | x | [114] |
| Oscarellin | *Oscarella stillans* | sponge | anthralinic acids | Decrease Activation of JNK | x | x | x | [115] |
| Lobocassin B | *Lobophytum crassum* | coral | diterpenoids | Downregulation of Th2 | IL-4 | IL-5 | IL-13 | IL-17 | [116] |
| Carijoside A | *Carijoa sp.* | soft coral | Steroid glycoside | Downregulation of Non-Th2 | IL-23 | IFN-γ | TNF-α | IL-33 | IL-1β | Inhibition of Inflammatory Response Shift: Th2 to Th17 | [117] |
| Klyflaccisteroid J | *Klyxum flaccidum* | soft coral | steroidal derivatives | | x | [118] |
| Klyflaccisteroid K-M | *Klyxum flaccidum* | soft coral | steroidal derivatives | | x | [119] |
| Rossinones A & B | *Aplidium species* | marine animals | Terpene derived metabolite | | x | [120] |
| 6-bromoisatin | *Dicathais orbita* | gastropod mollusc | brominated indole derivatives | | x | x | [121] |
| Didemnin B | *Trididemnum solidum* | ascidia | depsipeptides | | x | x | [122,123] |
Table 3. Cont.

| Compound                        | Specie               | Origin          | Class  | Molecular Targets | References |
|---------------------------------|----------------------|-----------------|--------|-------------------|------------|
|                                 |                      |                 |        | Downregulation of Th2 | Downregulation of Non-Th2 |             |
|                                 |                      |                 |        | IL-4              | IL-5       | IL-13  |
|                                 |                      |                 |        | IL-17             | IL-23      | IFN-γ  |
|                                 |                      |                 |        | TNF-α             | IL-33      | IL-1β  |
|                                 |                      |                 |        |                   | Inhibition of Inflammatory Response Shift Th2 to Th17 |
| Splenocins A-I                  | *Streptomyces sp.*   | bacteria        | depsipeptides | x                  | x          | x      | x       | x         | x         | [124] |
| Sinulerectol A & B              | *Sinularia erecta*   | soft coral      | cembranoids  | x                  |            |        |         |           |           | [125] |
| Complex composition             |                      |                 |        |                   |            |        |         |           |           |         |
| Sargassum horneri extract       | *Sargassum horneri*  | brown algae     | extract | x                  | x          | x      | x       |           |           | [126] |
| Sargassum horneri (Turner) C. Agardh ethanol extract | *Sargassum horneri* (Turner) C. Agardh | brown algae | extract | x                  | x          |         | x       |           |           | [127] |
| Sargassum horneri (Turner) ethanol extract | *Sargassum horneri* (Turner) C. Agardh | brown algae | extract | x                  | x          |         | x       |           |           | [128] |
| Sargassum horneri ethanol extract | *Sargassum horneri*  | brown algae     | ethanol extract | x                  | x          | x      | x       | x         |           | [86]  |
| Sargassum horneri (Turner) C. Agardh ethanol extract | *Sargassum horneri* (Turner) C. Agardh | brown algae | ethanolic extract | x                  | x          |         | x       | x         |           | [129] |
| Sargassum hemiphyllum methanol extract | *Sargassum hemiphyllum* | brown algae | methanol extract | x                  |         |         | x       |           |           | [130] |
| Sulfated polysaccharide         | *Saccharina japonica*| brown algae     | polysaccharides | x                  | x          | x      | x       | x         |           | [131] |
| Compound                                | Specie               | Origin      | Class                   | Molecular Targets                                                                 | References |
|-----------------------------------------|----------------------|-------------|-------------------------|-----------------------------------------------------------------------------------|------------|
| Sulfated polysaccharide                 | *Sargassum fulvellum*| brown algae | polysaccharides         | Decrease Activity of MAPK | Increase of Activity of HDAC | Decrease Activation of JNK | Decrease Activation of NF-κB | Decrease Oxidative Stress | IL-4 | IL-5 | IL-13 | IL-17 | IL-23 | IFN-γ | TNF-α | IL-33 | IL-1β | Inhibition of Inflammatory Response Shift: Th2 to Th17* |
| Exopolysaccharide (EPCP1-2)             | *Crypthecodium colnii*| microalgae  | polysaccharide          | x                           | x                           |                              | x                           | x                           |      |      |      |      |       |       |       |       |       |       | [133] |
| Cyanobacterial lipopolysaccharide       | *Oscillatoria planktothrix FP1* | bacteria  | lipopolysaccharides     | x                           |                              | x                           | x                           | [134–136] |
| Spirulina extract                       | *Arthrospira platensis (Spirulina)* | bacteria   | lipoproteins            | x                           |                              | x                           | x                           | [137,138] |
| Arctoscopus japonicus egg extracted lipids | *Arctoscopus japonicus* | fish       | fatty acid              | x                           | x                           | x                           | x                           | x                           | [139] |
| Apostichopus japonicus extract          | *Apostichopus japonicus* | marine animals | extract                  | x                           | x                           | x                           | x                           | x                           | [88] |

* inhibition of inflammatory response shift from Th2-derived airway eosinophilic inflammation to Th17-driven neutrophilic inflammation (through inhibition of LPS-induced release of pro-inflammatory cytokines).
**Table 4.** Chemical formula of marine drugs with potential use in glucocorticoid-resistant severe asthma.

| Compound                      | Chemical Structure |
|-------------------------------|--------------------|
| fucosterol                    | ![Fucosterol](image) |
| mojabanchromanol              | ![Mojabanchromanol](image) |
| sargachromenol                | ![Sargachromenol](image) |
| fucoidan                      | ![Fucoidan](image)   |
| 3,4,5,5-Tetramethyl-4-(3′-oxopentyl)-2-cyclohexen-1-one | ![Fucoidan](image) |

Some of these compounds from different marine sources are well characterized and have well-defined structures (Table 4), while others are extracts with complex compositions.

Some marine microalgae polysaccharides, bacteria lipopolysaccharides, bacteria lipoproteins, and fish fatty acid extracts have anti-inflammatory effects, while brown algae polysaccharides and sargassum extract also show anti-inflammatory effects.
Table 4. Cont.

| Compound                                                                 | Chemical Structure |
|--------------------------------------------------------------------------|--------------------|
| 4-hydroxy-2,3-dimethyl-2-nonen-4-olide                                    | ![Chemical Structure](image1) |
| (E)-9-Oxooctadec-10-enoic-acid and (E)-10-Oxooctadec-8-enoic-acid         | ![Chemical Structure](image2) |
| cyclo(L-Pro-D-Val), cyclo(L-Pro-L-Tyr), cyclo(L-pro-D-Leu)               | ![Chemical Structure](image3) |
| cycloprodigiosin                                                         | ![Chemical Structure](image4) |
| C-phycocyanin                                                            | ![Chemical Structure](image5) |
### Table 4. Cont.

| Compound                  | Chemical Structure |
|---------------------------|--------------------|
| phenazines 1,2            | ![Phenazine 1](image1.jpg) ![Phenazine 2](image2.jpg) |
| griseusrazin A            | ![Griseusrazin A](image3.jpg) |
| grassystatin A            | ![Grassystatin A](image4.jpg) |
| ogipeptins A-D            | ![Ogipeptins A-D](image5.jpg) |

(−)-1S-myrothecol and (+)-1R-myrothecol

chrysamides A–C
Table 4. Cont.

| Compound | Chemical Structure |
|----------|-------------------|
| pyrenocine A | ![Chemical Structure](image1.png) |
| (−)-1S-myrothecol and (+)-1R-myrothecol | ![Chemical Structure](image2.png) |
| chrysamides A–C | ![Chemical Structure](image3.png) |
| brevicompanine E | ![Chemical Structure](image4.png) |
| polyoxygenated dysidea sterols | ![Chemical Structure](image5.png) |
Table 4. Cont.

| Compound          | Chemical Structure |
|-------------------|--------------------|
| bolinaquinone     | ![Chemical Structure](image1.png) |
| hirsutanol A      | ![Chemical Structure](image2.png) |
| oscarellin        | ![Chemical Structure](image3.png) |
| lobocrassin B     | ![Chemical Structure](image4.png) |
| carijoside A      | ![Chemical Structure](image5.png) |
| klyflaccisteroid J| ![Chemical Structure](image6.png) |
Table 4. Cont.

| Compound                  | Chemical Structure |
|---------------------------|--------------------|
| klyflaccisteroid K-M      | ![Chemical Structure](image1.png) |

| rossinones A & B          | ![Chemical Structure](image2.png) |
|---------------------------|-----------------------------------|
| 6-bromoisatin             | ![Chemical Structure](image3.png) |

| didemnin B                | ![Chemical Structure](image4.png) |
4.1. Cellular Signal/Corticoresistance

β-secretion of pro-inflammatory cytokines (IL-6, IL-1β) and the reduction of the ROS-mediated phosphorylation of MAPK (including p38, ERK, and JNK) and NF-κB signaling pathways in a zebrafish experiment [91].

Using free-radical-scavenging assays antioxidant properties were discovered for the sesquiterpenoids in green algae Ulva fasciata Deliles [92,93].

An extract from Korean marine alga Ulva pertusa, 4-hydroxy-2,3-dimethyl-2-nonen-4-olide, moderately inhibited the release of the pro-inflammatory cytokines IL-12 p40 and IL-6 from bone marrow-derived dendritic cells, as well as signal transduction by inhibiting phosphorylation of NF-κB, and, thus, warranted further study to evaluate its potential as a “therapeutic agent for inflammation-associated maladies” [94].

Two fatty acids, (E)-9-Oxooctadec-10-enoic-acid and (E)-10-Oxooctadec-8-enoic-acid, isolated from Gracilaria verrucosa, inhibited the production of inflammatory biomarkers, including NO, IL-6, and TNF-α, by suppressing the nuclear translocation of NF-κB and the phosphorylation of STAT1 in LPS-stimulated RAW264.7 cells [95].

Three diketopiperazine derivatives, cyclo(L-Pro-D-Val), cyclo(L-Pro-L-Tyr), and cyclo(L-Pro-D-Leu), derived from two marine bacteria, Bacillus sp. HC001 and Piscicoccus sp. 12L081, demonstrated anti-inflammatory effects through the inhibition of p38 MAPK activation and the downregulation of TNF-α, IL-6, NF-kB, and ERK1/2 [96].

Cycloprodigiosin, an analog of prodigiosin obtained from Pseudoalteromonas dentrificans, inhibited TNF-α induced NF-κB activation in HeLa, U373, and COS7 cell lines [97,98].

C-Phycocyanin from Nostoc Muscorum cyanobacteria is a pigment with antioxidant potential [99,100].

Pyrenocine A, produced from the marine-derived fungus Penicillium paxilli, produces immunosuppressive effects through the inhibition of pro-inflammatory mediators (TNF-α and PGE2) and inhibits the expression of genes related to NFκB activation in macrophages stimulated with LPS [108].

Two new components, (-)-1S-myrothecol and (+)-1R-myrothecol, isolated from the deep-sea fungus Myrothecium sp. BZO-L062, presented anti-inflammatory and antioxidant activities [109].

Oscarellin, an anthranilic acid derivative isolated from Oscarella stillans, a Philippine sponge, strongly inhibits LPS-induced TNF-α and IL-6 production in murine macrophage RAW264.7. These changes are associated with the inactivation of c-Jun NH2-terminal

Table 4. Cont.

| Compound                | Chemical Structure |
|-------------------------|--------------------|
| splenocins A-I          | ![Chemical Structure](image1) |
| sinulerectol A & B      | ![Chemical Structure](image2) |
kinase (JNK), extracellular signal-regulated kinase (ERK), activator protein-1 (AP-1), and NF-κB, and the activation of activating transcription factor-3 (ATF-3) [115].

Lobocassin B, an extract from the soft coral Lobophytum crissum, inhibited the production of TNF-α and NF-κB, an important transcription factor responsible for cytokine production, in mouse dendritic cells [116].

Didemnin B (Depsipeptides) was extracted and isolated from Trididemnum solidum; it exhibited strong anti-inflammatory and immunosuppressive activity through the inhibition of iNOS and NF-κB [122,123].

Sargassum horneri ethanol extract, from an edible brown marine algae, demonstrated anti-inflammatory effects mediated by the phosphorylation of MAPK p38, extracellular signal-regulated kinase 1/2 (Erk1/2), and c-jNK, to induce the particulate matter-induced mRNA expression of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6), lung epithelial cell derived-chemokines (IL-8, MCP-1, and chemokine (CCL5), and to suppress the mRNA expression of particulate matter-induced pro-allergic cytokines thymic stromal lymphopoietin (TSLP) and IL-33 [126].

Sargassum horneri (Turner) C. Agardh ethanol extract (SHE), obtained from the brown algae Sargassum horneri, demonstrated anti-inflammatory and cytoprotective effects on macrophage cells as a model for alveolar lung cells, probably via the p38 MAPK pathway and Nrf2/HO-1 expression. The extract inhibited the production of inflammatory mediators (iNOS, COX-2, and PGE2) and pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) [127].

Another ethanol extract with a commercial grade of 70%, separated from Sargassum horneri, demonstrated similar effects: it significantly repressed the secretions of inflammatory cytokines and reduced protein expression in PGE2, TNF-α, IL-6, IL-1β, NF-κB, and MAPKs from PM-activated macrophages [128].

A sulfated polysaccharide with a sulfate content of 9.07% from Saccharina japonica showed significant inhibition of NO and PGE2 production via the downregulation of iNOS and COX-2 expression. The polysaccharide also suppressed TNF-α and (IL)-1β production via the NF-κB and MAPK signal pathways in LPS-induced RAW cells [131].

The fatty acids from the Arctoscopus japonicus egg of a cold-water marine fish presented anti-inflammatory effects through the suppression of the expression of iNOS, COX-2, IL-1β, IL-6, and TNF-α, and a reduction in the phosphorylation levels of NF-κB p-65, p38, ERK1/2, and JNK, key components of the NF-κB and MAPK pathways [139].

4.2. Cytokine Levels

4.2.1. Th2 Cytokines

The whole culture extract of a marine-derived actinomycete strain, culture CNQ431, identified as a Streptomyces sp., demonstrated potent suppression of Th2 cytokines IL-5 and IL-13, but also the production of the dendritic cell-associated cytokines IL-1 and TNF-α, indicating immunosuppressive effects on both the APCs (i.e., dendritic cells) and the Th2 cells in a mouse splenocyte assay [124].

An ethanol extract from Sargassum horneri, obtained from a brown alga, was found to have antioxidant, anti-inflammatory, and anti-allergic effects in a BALB/c mouse model of asthma sensitized with ovalbumin. IL-4, IL-5, and IL-13 were found to be decreased in the lungs of PM-exacerbated asthmatic mice. Concomitantly, the Th17 cell response, the expression of responses of relevant effector cytokines, IL-17a and Th2/Th17, were also decreased [86].

A methanol extract of Sargassum hemiphyllum, a brown seaweed, inhibited the increase of TNF-α-induced NF-κB protein levels, the transcription factor of TNF-α, and IL-8 and TNF-α release, suggesting an inhibitory effect on atopic allergic reactions [130].
Exopolysaccharide EPCP1-2, an extracellular polysaccharide extracted from *Crypthecodinium cohnii*, has significant potential to inhibit macrophage proliferation, as well as to downregulate the expression of TLR4, TAK1, MAPKs, and NF-κB protein. It acts as an anti-inflammatory agent through macrophage suppression on the RAW 264.7 macrophage cell line and is a potent regulatory MAPK, and NF-κB signaling pathways [133].

Spirulina extract (Immulina®), a high-molecular-weight polysaccharide extract from the cyanobacterium *Arthrospira platensis* (Spirulina), showed anti-inflammatory and inhibitory effects in an induced allergic inflammatory response and on histamine release from RBL-2H3 mast cells. It also has the potential to inhibit the IgE-antigen-complex-induced production of TNF-α, IL-4, leukotrienes, and histamine, and showed promising effects with respect to the relief of allergic rhinitis symptoms [137,138].

A component of this extract, n-hexane, a fatty-acid-rich fraction, ameliorated allergic airway inflammation in a mouse model of ovalbumin-induced asthma: eosinophil infiltration and goblet cell hyperplasia were significantly reduced around the airways, and the concentrations of Th2-related cytokines (IL-4, IL-5, and IL-13) and Th17-related cytokines (IL-17) were significantly decreased in the spleen and bronchoalveolar lavage fluid [88].

Phlorotannins isolated from brown algae, *Eckolonia cava*, exhibited anti-allergic activities through the inhibition of degranulation: the tested compounds suppressed the binding between IgE and FcεRI receptors [140].

Reticulol, a polyketide isolated from *Graphostroma* sp. MCCC 3A00421 deep-sea hydrothermal sulfide deposits from the Atlantic Ocean, showed potent inhibition of degranulation with an IC50 value of 13.5 μM [141].

Three compounds isolated from the deep-sea-derived marine *Williamsia* sp. MCCC 1A11233 (CDMW), CDMW-3, CDMW-5, and CDMW-15, demonstrated antiallergic activity due to the block of mast-cell-dependent passive cutaneous anaphylaxis in IgE-sensitized mice and to the decrease of degranulation and histamine release in immunoglobulin E (IgE)-mediated rat basophilic leukemia (RBL)-2H3 cells [142].

An extract of *Apostichopus japonicus*, obtained from a sea cucumber, showed antioxidant and anti-inflammatory effects in mice with ovalbumin-induced asthma. The hyper-responsiveness of airways was significantly lower, the number of eosinophils in the lungs was decreased, and T regulatory cells significantly increased in the mesenteric lymph nodes [143].

Peridinin and fucoxanthin, carotenoids isolated from *Symbiodinium* sp., a symbiotic dinoflagellate, and from *Petalonia fascia*, a brown alga, respectively, were shown to suppress allergic inflammatory responses through the inhibition of delayed-type hypersensitivity in mice, and to reduce the number of eosinophils in both the ear lobe and peripheral blood. The inhibitory effect of peridinin was higher than that of fucoxanthin [144].

4.2.2. Th17/Non Th2 Cytokines

Two novel phenazines, obtained from marine-derived *Streptomyces* sp., showed anti-inflammatory potential and inhibited the production of LPS-induced NO, TNF-α-induced NFKB activity [101–104].

Griseusrazin A, a pyrazine derivative produced from marine *Streptomyces griseus*, inhibited the production of pro-inflammatory cytokines, such as IL-1β, IL-6, and TNF-α, in LPS-stimulated cells and suppressed iNOS [103,105].

Grassystatin A, obtained from the cyanobacterium *Lyngbya confervoides*, inhibited the upregulation of IL-17 and interferon-γ (INF-γ) in response to antigen presentation, reduced T cell proliferation in a dose-dependent manner, and inhibited the upregulation of IL-17 and IFN-γ in response to antigen presentation [106].

Ogipeptins A-D, obtained from the culture broth of the Japanese marine Gram-negative bacterium *Pseudoalteromonas* sp. SANK 71903, decreased TNF-α release by human U937 monocytic cells [107].
Three chrysamides, A–C, dimeric nitrophenyl trans-epoxyamides obtained from the deep-sea-derived fungus, *Penicillium chrysogenum* SCSIO41001, suppressed the production of proinflammatory cytokine IL-17 [110].

Brevicompanine E, isolated from a deep ocean sediment-derived fungus, *Penicillium* sp., was found to inhibit LPS-induced TNF-α, IL-1β, iNOS and COX-2 production in microglia and LPS-induced IkBα degradation, NF-κB nuclear translocation, and Akt, c-Jun NH2-terminal kinase (JNK) phosphorylation [111].

Bolinaquinone, a polyoxygenated sterol derived from *Dysidea* sp., inhibited LPS-induced TNF-α, IL-1β, iNOS and COX-2 production in microglia and LPS-induced IkBα degradation, NF-κB nuclear translocation, and Akt, c-Jun NH2-terminal kinase (JNK) phosphorylation [111].

Hirsutanol A (HA), isolated from a red alga-derived fungus, *Chondrostereum* sp. NTOU4196, significantly attenuated the levels of TNF-α, IL-6, and IL-1β in LPS-treated THP-1 cells [114].

Carjioside, a steroid glycoside extracted from *Carijoa* sp., inhibited the superoxide anion generation and elastase release by human neutrophils [117]. On the other hand, rossinones A and B, terpene-derived metabolites of the Aplidium species ascidian family of *Polyclinidae*, inhibited only the superoxide production [120].

Klyflaccisteroid J, a steroid isolated from the Formosan soft coral *Klyxum flaccidum*, demonstrated suppression of N-formyl-methionyl-leucylphenyl-alanine/cytochalasin B (fMLP/CB)-induced superoxide anion generation and elastase release in human neutrophils in vitro [118]. New steroids, klyflaccisteroids K–M, also isolated from *Klyxum flaccidum*, demonstrated the suppression of superoxide anion generation and elastase release [119].

A brominated indol isolated from the gastropod mollusk *Dicathais orbita*, 6-bromoindol, inhibited inflammation in a murine model of LPS-induced acute lung injury by significantly reducing TNF-α and IL-1β production and associated lung damage [121].

Sinulerectol A and Sinulerectol B, as extracts isolated from the marine soft coral *Sinularia erecta*, showed anti-inflammatory activities in neutrophil pro-inflammatory responses [125].

*Sargassum horneri* (Turner), a C. Agardh ethanolic extract with 70% ethanol lyophilized at −40 °C, obtained from a brown alga, showed antioxidant and anti-inflammatory effects through a dose-dependent reduction of the mRNA level of cytokines, including IL-1β, and pro-inflammatory genes, such as iNOS and COX-2, in LPS-stimulated macrophage activation. In addition, the anti-inflammatory effects were obtained by inhibiting ERK, p-p38 and NF-κB phosphorylation and by the release of IL-1β in LPS-stimulated macrophages [129].

A cyanobacterial lipopolysaccharide, isolated from *Oscillatoria planktothrix* FP1, demonstrated anti-inflammatory effects through the inhibition of LPS-induced IL-1β, TNF-α, and IL-8 production [134–136].

5. Conclusions

In recent years, efforts have been made to understand the mechanisms underlying GC resistance. To overcome GC resistance, which is frequently associated with high doses of GC treatment, there is an urgent need for more specific targeted therapies. Natural compounds have been demonstrated to be effective against various pathological mechanisms through a variety of pathways. Some of these mechanisms were also shown to be involved in GC resistance. This paper reviewed the marine compounds potentially acting on the mechanisms involved in GC-resistant severe asthma. The article provided a basis for the development of effective marine-derived drugs as new and safe sources for the potential treatment of glucocorticoid-resistant severe asthma.

Author Contributions: Conceptualization, methodology, writing—original draft preparation, and writing—review and editing, C.M.G., A.G.V., C.S.S., S.A.A. and P.P. All authors have read and agreed to the published version of the manuscript.

Funding: Doctoral Scholarship from Grigore T. Popa University of Medicine and Pharmacy of Iasi, Romania (for A.G.V.).

Institutional Review Board Statement: Not applicable.
References

1. Borna, E.; Nwaru, B.I.; Bjerg, A.; Mincheva, R.; Rådinger, M.; Lundbäck, B.; Ekerljung, L. Changes in the Prevalence of Asthma and Respiratory Symptoms in Western Sweden between 2008 and 2016. Allergy 2019, 74, 1703–1715. [CrossRef]

2. Hekking, P.-P.W.; Wener, R.R.; Amelink, M.; Zwediumer, A.H.; Bouvy, M.L.; Bel, E.H. The Prevalence of Severe Refractory Asthma. J. Allergy Clin. Immunol. 2015, 135, 896–902. [CrossRef]

3. Chung, K.F.; Wenzel, S.E.; Brozek, J.L.; Bush, A.; Castro, M.; Sterk, P.J.; Adcock, I.M.; Bateman, E.D.; Bel, E.H.; Bleeker, E.R.; et al. International ERS/ATS Guidelines on Definition, Evaluation and Treatment of Severe Asthma. Eur. Respir. J. 2014, 43, 343–373. [CrossRef]

4. O’Neill, S.; Pattern, I.C.; Crompton, G.K.; Kay, A.B.; Grant, I.W. Corticosteroid Resistance in Chronic Asthma. Thorax 2012, 67, 716–725. [CrossRef]

5. Global Initiative for Asthma. Available online: https://ginasthma.org/ (accessed on 27 September 2021).

6. Carmichael, J.; Paterson, I.C.; Diaz, P.; Crompton, G.K.; Kay, A.B.; Grant, I.W. Corticosteroid Resistance in Chronic Asthma. Thorax 2012, 67, 716–725. [CrossRef]

7. Barnes, P.J.; Greening, A.P.; Crompton, G.K. Glucocorticoid Resistance in Asthma. Am. J. Respir. Crit. Care Med. 1995, 152 Pt 2, S125–S140. [CrossRef] [PubMed]

8. Löwhagen, O. Diagnosis of Asthma—New Theories. J. Asthma 2015, 52, 538–544. [CrossRef]

9. Barreca, M.; Spanò, V.; Montalbano, A.; Cueto, M.; Díaz Marrero, A.R.; Deniz, I.; Erdoğan, A.; Lukić Bilela, L.; Moulin, C.; Taffin-de-Givenceny, E.; et al. Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes. Mar. Drugs 2020, 18, 619. [CrossRef]

10. Chen, G.; Seupek, A.J.; Guo, M. Recent Advances in Molecular Docking for the Research and Discovery of Potential Marine Drugs. Mar. Drugs 2020, 18, 945. [CrossRef] [PubMed]

11. Grosso, C.; Valentina, P.; Ferreres, F.; Andrade, P.B. Bioactive Marine Drugs and Marine Biomaterials for Brain Diseases. Mar. Drugs 2014, 12, 2539–2589. [CrossRef]

12. Mayer, A.M.S.; Guerrero, A.J.; Rodríguez, A.D.; Taglialetela-Scafati, O.; Nakamura, F.; Fusetti, N. Marine Pharmacology in 2014–2015: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis, Antiviral, and Anthelmintic Activities; Affecting the Immune and Nervous Systems, and Other Miscellaneous Mechanisms of Action. Mar. Drugs 2019, 18, 5. [CrossRef]

13. Mayer, A.M.S.; Guerrero, A.J.; Rodríguez, A.D.; Taglialetela-Scafati, O.; Nakamura, F.; Fusetti, N. Marine Pharmacology in 2016–2017: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis and Antiviral Activities; Affecting the Immune and Nervous Systems, and Other Miscellaneous Mechanisms of Action. Mar. Drugs 2021, 19, 49. [CrossRef] [PubMed]

14. Yun, C.W.; Kim, H.J.; Lee, S.H. Therapeutic Application of Diverse Marine-Derived Natural Products in Cancer Therapy. Anticancer Res. 2019, 39, 5261–5284. [CrossRef]

15. Zhou, J.-B.; Luo, R.; Zheng, Y.-L.; Fang, J.-Y. Recent Advances in the Discovery and Development of Marine Natural Products with Cardiovascular Pharmacological Effects. Mini Rev. Med. Chem. 2018, 18, 527–550. [CrossRef] [PubMed]

16. Bilal, M.; Qindeel, M.; Nunes, L.V.; Duarte, M.T.S.; Ferreira, L.F.R.; Soriano, R.N.; Iqbal, H.M.N. Marine-Derived Biologically Active Compounds for the Potential Treatment of Rheumatoid Arthritis. Mar. Drugs 2020, 18, 257. [CrossRef] [PubMed]

17. Báquero, A.F.; Chirico, C.; Grumazescu, A.M. Marine Biocompounds for Neuroprotection—A Review. Mar. Drugs 2020, 18, 290. [CrossRef]

18. Wenzel, S.E. Asthma Phenotypes: The Evolution from Clinical to Molecular Approaches. Nat. Med. 2012, 18, 716–725. [CrossRef]

19. Chambers, E.S.; Nanzer, A.M.; Pfeifer, P.E.; Richards, D.F.; Timms, P.M.; Martineau, A.R.; Griffiths, C.J.; Corrigan, C.J.; Hawrylowicz, C.M. Distinct Endotypes of Steroid-Resistant Asthma Characterized by IL-17A High and IFN-θ High Immunophenotypes: Potential Benefits of Calcitriol. J. Allergy Clin. Immunol. 2015, 136, 628–637.e4. [CrossRef] [PubMed]

20. Keenan, C.R.; Radovicic, D.; Li, M.; Radwan, A.; Stewart, A.G. Heterogeneity in Mechanisms Influencing Glucocorticoid Sensitivity: The Need for a Systems Biology Approach to Treatment of Glucocorticoid-Resistant Inflammation. Pharmacol. Ther. 2015, 150, 81–93. [CrossRef]

21. Barnes, P.J.; Adcock, I.M. Glucocorticoid Resistance in Inflammatory Diseases. Lancet 2009, 373, 1905–1917. [CrossRef]

22. Barnes, P.J. Corticosteroid Resistance in Patients with Asthma and Chronic Obstructive Pulmonary Disease. J. Allergy Clin. Immunol. 2013, 131, 636–645. [CrossRef] [PubMed]

23. Keenan, C.R.; Salem, S.; Fietz, E.R.; Gualano, R.C.; Stewart, A.G. Glucocorticoid-Resistant Asthma and Novel Anti-Inflammatory Drugs. Drug Discov. Today 2012, 17, 1031–1035. [CrossRef]

24. Scheschowitsch, K.; Leite, J.A.; Assreuy, J. New Insights in Glucocorticoid Receptor Signaling—More Than Just a Ligand-Binding Receptor. Front. Endocrinol. (Lausanne) 2017, 8, 16. [CrossRef]

25. Oakley, R.H.; Sar, M.; Cidlowski, J.A. The Human Glucocorticoid Receptor β Isoform: Expression, Biochemical Properties, and Putative Function. J. Biol. Chem. 1996, 271, 9550–9559. [CrossRef]
26. Charmandari, E.; Chrousos, G.P.; Ichijo, T.; Bhattacharyya, N.; Vottero, A.; Souvatzoglou, E.; Kino, T. The Human Glucocorticoid Receptor (HGR) β Isoform Suppresses the Transcriptional Activity of HGRα by Interfering with Formation of Active Coactivator Complexes. *Mol. Endocrinol.* 2005, 19, 52–64. [CrossRef] [PubMed]

27. Stahn, C.; Buttgereit, F. Genomic and Nongenomic Effects of Glucocorticoids. *Nat. Rev. Rheumatol.* 2008, 4, 525–533. [CrossRef]

28. Galigniana, M.D.; Echeverría, P.C.; Erlejman, A.G.; Pivven-Pilipuk, G. Role of Molecular Chaperones and TPR-Domain Proteins in the Cytoplasmic Transport of Steroid Receptors and Their Passage through the Nuclear Fores. *Nucleus* 2010, 1, 299–308. [CrossRef]

29. Galon, J.; Franchimont, D.; Hiroi, N.; Frey, G.; Boettner, A.; Ehhrath-Bornstein, M.; O’Shea, J.J.; Chrousos, G.P.; Bornstein, S.R. Gene Profiling Reveals Unknown Enhancing and Suppressive Actions of Glucocorticoids on Immune Cells. *EASEB J.* 2002, 16, 61–71. [CrossRef] [PubMed]

30. Dennis, M.; Itkin, I.H. Effectiveness and Complications of Aerosol Dexamethasone Phosphate in Severe Asthma. *J. Allergy 1964, 35, 70–76*. [CrossRef]

31. Schwiebert, L.A.; Beck, L.A.; Stellato, C.; Bickel, C.A.; Bochner, B.S.; Schleimer, R.P. Glucocorticosteroid Inhibition of Cytokine Production: Relevance to Antiallergic Actions. *J. Allergy Clin. Immunol.* 1996, 97 Pt 2, 143–152. [CrossRef]

32. Alangari, A.A. Genomic and Non-Genomic Actions of Glucocorticoids in Asthma. *Ann. Thorac. Med.* 2010, 5, 133. [CrossRef]

33. Hirst, S.J.; Lee, T.H. Airway Smooth Muscle as a Target of Glucocorticoid Action in the Treatment of Asthma. *Am. J. Respir. Crit. Care Med.* 1998, 158 (Suppl. S2), S201–S206. [CrossRef]

34. Zhou, J.; Liu, D.-F.; Liu, C.; Kang, Z.-M.; Shen, X.-H.; Chen, Y.-Z.; Xu, T.; Jiang, C.-L. Glucocorticoids Inhibit Degranulation of Mast Cells in Allergic Asthma via Nongenomic Mechanism. *Allergy* 2008, 63, 1177–1185. [CrossRef]

35. Ayraldi, E.; Cannarile, L.; Migliorati, G.; Nocentini, G.; Delfino, D.V.; Riccardi, C. Mechanisms of the Anti-Inflammatory Effects of Glucocorticoids: Genomic and Nongenomic Interference with MAPK Signalling Pathways. *EASEB J.* 2012, 26, 4805–4820. [CrossRef] [PubMed]

36. Tantisira, K.G.; Lasky-Su, J.; Harada, M.; Murphy, A.; Litonjua, A.A.; Himes, B.E.; Lange, C.; Lazarus, R.; Syliva, J.; Klanderman, B.; et al. Genomewide Association between GLCCI1 and Response to Glucocorticoid Therapy in Asthma. *N. Engl. J. Med.* 2011, 365, 1173–1183. [CrossRef]

37. Keskin, O.; Uluca, Ü.; Birben, E.; Co¸ skun, Y.; Ozkars, M.Y.; Keskin, M.; Kucukosmanoglu, E.; Kalayci, O. Genetic Associations of the Reponse to Inhaled Corticosteroids in Children during an Asthma Exacerbation. *Pediatr. Allergy Immunol. 2016, 27, 507–513*. [CrossRef]

38. Hu, C.; Xun, Q.; Li, X.; He, R.; Lu, R.; Zhang, S.; Hu, X.; Feng, J. GLCCI1 Variation Is Associated with Asthma Susceptibility and Inhaled Corticosteroid Response in a Chinese Han Population. *Arch. Med. Res.* 2016, 47, 118–125. [CrossRef] [PubMed]

39. Weigel, N.L.; Moore, N.L. Steroid Receptor Phosphorylation: A Key Modulator of Multiple Receptor Functions. *Mol. Endocrinol. 2007, 21, 2311–2319*. [CrossRef]

40. Adcock, I.M.; Lane, S.J.; Brown, C.R.; Lee, T.H.; Barnes, P.J. Abnormal Glucocorticoid Receptor-Activator Protein 1 Interaction in Steroid-Resistant Asthma. *J. Exp. Med.* 1995, 182, 1951–1958. [CrossRef] [PubMed]

41. Ramamooorthy, S.; Cidlowski, J.A. Ligand-Induced Repression of the Glucocorticoid Receptor Gene Is Mediated by an NCoR1 Repression Complex Formed by Long-Range Chromatin Interactions with Intragenic Glucocorticoid Response Elements. *Mol. Cell. Biol.* 2013, 33, 1711–1722. [CrossRef]

42. Vazquez-Tello, A.; Halwani, R.; Hamid, Q.; Al-Muhsen, S. Glucocorticoid Receptor-beta up-Regulation and Steroid Resistance Induction by IL-17 and IL-23 Cytokine Stimulation in Peripheral Mononuclear Cells. *J. Clin. Immunol.* 2013, 33, 466–478. [CrossRef]

43. Iruen, E.; Matthews, J.G.; Takahashi, A.; Barnes, P.J.; Chung, K.F.; Adcock, I.M. P38 Mitogen-Activated Protein Kinase–Induced Glucocorticoid Receptor Phosphorylation Reduces Its Activity: Role in Steroid-Insensitive Asthma. *J. Allergy Clin. Immunol.* 2002, 109, 649–657. [CrossRef] [PubMed]

44. Adcock, I.M. Glucocorticoid-Regulated Transcription Factors. *Palm. Pharmacol. Ther.* 2001, 14, 211–219. [CrossRef]

45. Leung, D.Y.; Martin, R.J.; Szefler, S.J.; Sher, E.R.; Ying, S.; Kay, A.B.; Hamid, Q. Dysregulation of Interleukin 4, Interleukin 5, and Interferon Gamma Gene Expression in Steroid-Resistant Asthma. *J. Exp. Med.* 1995, 181, 33–40. [CrossRef] [PubMed]

46. Gurgone, D.; McShane, L.; McSharry, C.; Guzik, T.J.; Maffia, P. Cytokines at the Interplay Between Asthma and Atherosclerosis? *Front. Pharmacol.* 2020, 11, 166. [CrossRef] [PubMed]

47. Peters, M.C.; Wenzel, S.E. Intersection of Biology and Therapeutics: Type 2 Targeted Therapeutics for Adult Asthma. *Lancet* 2020, 395, 371–383. [CrossRef]

48. Ito, K.; Yamamura, S.; Essilfie-Quaye, S.; Cosio, B.; Ito, M.; Barnes, P.J.; Adcock, I.M. Histone Deacetylase 2–Mediated Deacetylation of the Glucocorticoid Receptor Enables NF-KB Suppression. *J. Exp. Med.* 2005, 203, 7–13. [CrossRef]

49. Bhavsar, P.; Hew, M.; Khorasani, N.; Taib, Z.; Asimus, S.; Hegeland-Myrbäck, T.; Lundin, S.; Pardali, K.; Kurian, N.; Ersdal, E.; et al. The Development of AZD7624 for Prevention of Exacerbations in COPD: A Randomized Controlled Trial. *Int. J. Chron. Obstruct. Palm. Dis.* 2018, 13, 1009–1019. [CrossRef] [PubMed]

50. Patel, N.R.; Cunoosamy, D.M.; Fagerás, M.; Taib, Z.; Asimus, S.; Hegeland-Myrbäck, T.; Lundin, S.; Pardali, K.; Kurian, N.; Ersdal, E.; et al. The Development of AZD7624 for Prevention of Exacerbations in COPD: A Randomized Controlled Trial. *Int. J. Chron. Obstruct. Palm. Dis.* 2018, 13, 1009–1019. [CrossRef] [PubMed]

51. Li, L.; Leung, D.Y.M.; Goleva, E. Activated P38 MAPK in Peripheral Blood Monocytes of Steroid Resistant Asthmatics. *PLoS ONE 2015, 10, e0141909*. [CrossRef]
52. Spears, M.; Donnelly, I.; Jolly, L.; Brannigan, M.; Ito, K.; McSharry, C.; Lafferty, J.; Chaudhuri, R.; Braganza, G.; Adcock, I.M.; et al. Effect of Low-Dose Theophylline plus Beclometasone on Lung Function in Smokers with Asthma: A Pilot Study. *Eur. Respir. J.* 2009, 33, 1010–1017. [CrossRef] [PubMed]

53. Mercado, N.; Hakim, A.; Kobayashi, Y.; Meah, S.; Usman, O.S.; Chung, K.F.; Barnes, P.J.; Ito, K. Restoration of Corticosteroid Sensitivity by P38 Mitogen Activated Protein Kinase Inhibition in Peripheral Blood Mononuclear Cells from Severe Asthma. *PLoS ONE* 2012, 7, e4182. [CrossRef]

54. Bi, J.; Min, Z.; Yuan, H.; Jiang, Z.; Mao, R.; Zhu, T.; Liu, C.; Zeng, Y.; Song, J.; Du, C.; et al. PI3K Inhibitor Treatment Ameliorates the Glucocorticoid Insensitivity of PBMCs in Severe Asthma. *Clin. Transl. Med.* 2020, 9, 22. [CrossRef]

55. Ito, K.; Lim, S.; Caramori, G.; Chung, K.F.; Barnes, P.J.; Adcock, I.M. Cigarette Smoking Reduces Histone Deacetylase 2 Expression, Enhances Cytokine Expression, and Inhibits Glucocorticoid Actions in Alveolar Macrophages. *FASEB J.* 2001, 15, 1110–1112. [CrossRef]

56. Ismaili, N.; Garabedian, M.J. Modulation of Glucocorticoid Receptor Function via Phosphorylation. *Am. J. Respir. Crit. Care Med.* 2014, 190, 1094–1101. [CrossRef]
75. Morishima, Y.; Ano, S.; Ishii, Y.; Ohtsuka, S.; Matsuyama, M.; Kawaguchi, M.; Hizawa, N. Th17-Associated Cytokines as a Therapeutic Target for Steroid-Insensitive Asthma. *Clin. Dev. Immunol.* 2013, 2013, 609395. [CrossRef] [PubMed]

76. Vazquez-Tello, A.; Semlali, A.; Chakir, J.; Martin, J.G.; Leung, D.Y.; Eidelman, D.H.; Hamid, Q. Induction of Glucocorticoid Receptor-β Expression in Epithelial Cells of Asthmatic Airways by T-Helper Type 17 Cytokines. *Clin. Exp. Allergy* 2010, 40, 1312–1322. [CrossRef]

77. Kim, H.Y.; Lee, H.J.; Chang, Y.-J.; Pichavant, M.; Shore, S.A.; Fitzgerald, K.A.; Ikawara, Y.; Israel, E.; Bolger, K.; Faul, J.; et al. Interleukin-17 Producing Innate Lymphoid Cells and the NLRP3 Inflammasome Facilitate Obesity-Associated Airway Hyperactivity. *Nat. Med.* 2014, 20, 54–61. [CrossRef]

78. Brandt, E.B.; Khurana Hershey, G.K. A Combination of Dexamethasone and Anti-IL-17A Treatment Can Alleviate Diesel Exhaust Particle-Induced Steroid Insensitive Asthma. *J. Allergy Clin. Immunol.* 2016, 138, 924–928.e2. [CrossRef]

79. Zhao, S.; Jiang, Y.; Yang, X.; Guo, D.; Wang, Y.; Wang, J.; Wang, R.; Wang, C. Lipopolysaccharides Promote a Shift from Th2-Derived Airway Eosinophilic Inflammation to Th17-Derived Neutrophilic Inflammation in an Ovalbumin-Sensitized Murine Asthma Model. *J. Asthma* 2017, 54, 447–455. [CrossRef]

80. Hawrylowicz, C.; Richards, D.; Loke, T.-K.; Corrigan, C.; Lee, T. A Defect in Corticosteroid-Induced IL-10 Production in T Lymphocytes from Corticosteroid-Resistant Asthmatic Patients. *J. Allergy Clin. Immunol.* 2002, 109, 369. [CrossRef]

81. Hirahara, K.; Mato, N.; Hagiwara, K.; Nakayama, T. The Pathogenicity of IL-33 on Steroid-Resistant Eosinophilic Inflammation via the Activation of Memory-Type ST2+CD4+ T Cells. *J. Leukoc. Biol.* 2018, 104, 895–901. [CrossRef]

82. Bray, P.J.; Cotton, R.G.H. Variations of the Human Glucocorticoid Receptor Gene (NR3C1): Pathological and in Vitro Mutations and Polymorphisms. *Hum. Mutat.* 2003, 21, 557–568. [CrossRef]

83. Cruz-Topete, D.; Cidlowski, J.A. One Hormone, Two Actions: Anti- and Pro-Inflammatory Effects of Glucocorticoids. *Neuroimmunomodulation* 2015, 22, 20–32. [CrossRef]

84. Herath, K.H.I.N.M.; Kim, H.J.; Jang, J.-H.; Kim, H.-S.; Kim, H.J.; Jeon, Y.-J.; Lee, D.-S.; Lee, J.-M.; Yim, M.-J.; Wang, L.; et al. Particulate Matter-Induced Attenuation of Cytokine Production in CpG-Stimulated Bone Marrow-Derived Dendritic Cells. *Chem. Biol.* 2018, 25, 539–545. [CrossRef]

85. Jayawardena, T.U.; Sanjeewa, K.K.A.; Lee, H.-G.; Nagahawatta, D.P.; Yang, H.-W.; Kang, M.-C.; Jeon, Y.-J.; Lee, D.-S.; Lee, J.-M.; Yim, M.-J.; Wang, L.; et al. Sargassum horneri Extract Containing Sargachromenol Attenuates the Particulate Matter Exacerbated Allergic Asthma through Reduction of Th2 and Th17 Response in Mice. *Environ. Pollut.* 2020, 265, 114094. [CrossRef]

86. Huang, J.; Su, M.; Lee, B.-K.; Kim, M.-J.; Jung, J.H.; Im, D.-S. Suppressive Effect of 4-Hydroxy-2-(4-Hydroxyphenethyl) Isoindoline-1,3-Dione on Ovalbumin-Induced Allergic Asthma. *Biomol. Ther.* 2018, 26, 539–545. [CrossRef]

87. Lee, D.-I.; Kang, S.A.; Md, A.; Jeong, U.-C.; Jin, F.; Kang, M.-C.; Lee, J.-Y.; Yu, H.S. Sea Cucumber Lipid-Soluble Extra Fraction Prevents Ovalbumin-Induced Allergic Airway Inflammation. *J. Med. Food* 2018, 21, 21–29. [CrossRef]

88. Jayawardena, T.U.; Sanjeewa, K.K.A.; Lee, H.-G.; Nagahawatta, D.P.; Yang, H.-W.; Kang, M.-C.; Jeon, Y.-J.; Particulate Matter-Induced Inflammation/Oxidative Stress in Macrophages: Fucosterol from Padina boryana as a Potent Protagonist, Activator via NF-KB/MAPK Pathways and Nrf2/HO-1 Involvement. *Mar. Drugs* 2020, 18, 628. [CrossRef]

89. Han, E.-J.; Jayawardena, T.U.; Jang, J.-H.; Fernando, I.P.S.; Lee, Y.; Jeon, Y.-J.; Lee, D.-S.; Lee, J.-M.; Yim, M.-J.; Wang, L.; et al. Sargachromenol Purified from Sargassum horneri Inhibits Inflammatory Responses via Activation of Nrf2/HO-1 Signaling in LPS-Stimulated Macrophages. *Mar. Drugs* 2019, 17, 499–804. [CrossRef] [PubMed]

90. Herath, K.H.I.N.M.; Kim, H.J.; Jeon, Y.-J.; Lee, D.-S.; Kim, H.-S.; Jeon, Y.-J.; Lee, H.-G.; Han, E.-J.; Jeong, U.-C.; Jin, F.; Kang, M.-C.; et al. Particulate Matter-Induced Attenuation of Cytokine Production in CpG-Stimulated Bone Marrow-Derived Dendritic Cells. *Food Funct.* 2021, 12, 355–369. [CrossRef] [PubMed]

91. Chen, X.; Li, N.; Fu, X.; Wang, L.; Duan, D.; Huang, L.; Xu, J.; Gao, X. Molecular Mechanism of Anti-Inflammatory Activities of a Novel Sulfated Galactofucan from Saccharina japonica. *Mar. Drugs* 2021, 19, 430. [CrossRef]

92. Chakraborty, K.; Paulraj, R. Sesquiterpenoids with Free-Radical-Scavenging Properties from Marine Macroalga Gracilaria verrucosa. *Int. Ed. Chem. Biol.* 2009, 38, 257–265. [CrossRef]

93. Shah, S.A.A.; Hassan, S.S.U.; Bungau, S.; Si, Y.; Xu, H.; Rahman, M.H.; Behl, T.; Gitea, D.; Pavel, F.-M.; Corb Aron, R.A.; et al. Chemically Diverse and Biologically Active Secondary Metabolites from Marine Phylum Chlorophyta. *Food Chem.* 2010, 122, 31–41. [CrossRef]

94. Staiger, B. Pro-inflammatory Macrophages and Staphylococcus Aureus in the Lung. *Hum. Mutat.* 2018, 39, 125–134. [CrossRef]

95. Förstner, A. Chemistry and Biology of Roseophilin and the Prodigiosin Alkaloids: A Survey of the Last 2500 Years. *Angew. Chem. Int. Ed.* 2003, 42, 3582–3603. [CrossRef]

96. Kamata, K.; Okamoto, S.; Oka, S.; Kamata, H.; Yagisawa, H.; Hirata, H. Cycloprodigiosin Hydrochloride Suppresses Tumor Necrosis Factor (TNF) Alpha-Induced Transcriptional Activation by NF-KappaB. *FEBS Lett.* 2001, 507, 74–80. [CrossRef]
125. Huang, C.-Y.; Tseng, Y.-J.; Chokkalingam, U.; Hwang, T.-L.; Hsu, C.-H.; Dai, C.-F.; Sung, P.-J.; Sheu, J.-H. Bioactive Isoprenoid-Derived Natural Products from a Dongsha Atoll Soft Coral *Sulunaria erecta*. *J. Nat. Prod.* 2016, 79, 1339–1346. [CrossRef] [PubMed]

126. Herath, K.H.I.M.N.; Kim, H.J.; Lee, J.H.; Je, J.G.; Yu, H.-S.; Jeon, Y.-J.; Kim, H.J.; Lee, Y. *Sargassum horneri* (Turner) C. Agardh Containing Polyphenols Attenuates Particulate Matter-Induced Inflammatory Response by Blocking TLR4-Mediated Lipopolysaccharide Signaling Pathway in MLE-12 Cells. *J. Ethnopharmacol.* 2021, 265, 113340. [CrossRef]

127. Jayawardena, T.U.; Asanka Sanjeewa, K.K.; Shanura Fernando, I.P.; Ryu, B.M.; Kang, M.-C.; Jeon, Y.-J.; Lee, W.W.; Jeon, Y.-J. *Sargassum horneri* (Turner) C. Agardh Ethanol Extract Inhibits the Fine Dust Inflammation Response via Activating Nrf2/HO-1 Signaling in RAW 264.7 Cells. *BMC Complement. Altern. Med.* 2018, 18, 249. [CrossRef]

128. Sanjeewa, K.K.A.; Jayawardena, T.U.; Kim, S.-Y.; Lee, H.G.; Je, J.-G.; Lee, Y.; Jeon, Y.-J. *Sargassum horneri* (Turner) Inhibit Urban Particulate Matter-Induced Inflammation in MH-S Lung Macrophages via Blocking TLR4 Mediated NF-KB and MAPK Activation. *J. Ethnopharmacol.* 2020, 249, 112363. [CrossRef] [PubMed]

129. Kim, M.E.; Jung, Y.C.; Jung, I.; Lee, H.-W.; Youn, H.-Y.; Lee, J.S. Anti-Inflammatory Effects of Ethanolic Extract from *Arctoscopus japonicus* Eggs on LPS-Stimulated RAW 264.7 Cells. *Mar. Drugs* 2016, 14, 253. [CrossRef] [PubMed]

130. Na, H.-J.; Moon, P.-D.; Ko, S.-G.; Lee, H.-J.; Jung, H.-A.; Hong, S.-H.; Seo, Y.; Oh, J.-M.; Lee, B.-H.; Choi, B.-W.; et al. Sargassum *halimenum* Inhibits Allergic Responses. *J. Pharmacol. Sci.* 2005, 97, 219–226. [CrossRef] [PubMed]

131. Wang, S.; Ni, L.; Fu, X.; Duan, D.; Xu, J.; Gao, X. A Sulfated Polysaccharide from *Saccharina japonica* Suppresses LPS-Induced Inflammation Both in a Macrophage Cell Model via Blocking MAPK/NF-KB Signal Pathways In Vitro and a Zebrafish Model of Embryos and Larvae In Vivo. *Mar. Drugs* 2020, 18, 593. [CrossRef]

132. Wang, L.; Yang, H.-W.; Ahn, G.; Fu, X.; Xu, J.; Gao, X.; Jeon, Y.-J. In Vitro and In Vivo Anti-Inflammatory Effects of Sulfated Polysaccharides Isolated from the Edible Brown Seaweed, *Sargassum fulvellum*. *Mar. Drugs* 2021, 19, 277. [CrossRef] [PubMed]

133. Ma, X.; Xie, B.; Du, J.; Zhang, A.; Hao, J.; Wang, S.; Wang, J.; Cao, J. The Anti-Inflammatory Effect and Structure of EPCP1-2 from *Cryptothecodium cohnii* via Modulation of TLR4-NF-KB Pathways in LPS-Induced RAW 264.7 Cells. *Mar. Drugs* 2017, 15, 376. [CrossRef] [PubMed]

134. Macagno, A.; Molteni, M.; Rinaldi, A.; Bertoni, F.; Lanzavecchia, A.; Rossetti, C.; Sallusto, F. A Cyanobacterial LPS Antagonist Prevents Endotoxin Shock and Blocks Sustained TLR4 Stimulation Required for Cytokine Expression. *J. Exp. Med.* 2006, 203, 1481–1492. [CrossRef] [PubMed]

135. Thorgersen, E.B.; Macagno, A.; Rossetti, C.; Mollnes, T.E. Cyanobacterial LPS Antagonist (CyP)-a Novel and Efficient Inhibitor of Actinomycete williamsia Sp. MCCC 1A11233 Variant on IgE-Mediated Mast Cells and Passive Cutaneous Anaphylaxis. *Toxins* 2018, 10, 290. [CrossRef]

136. Molteni, M.; Bosi, A.; Rossetti, C.; Thiemann, E. Cyanobacterial LPS Antagonist (CyP)-a Novel and Efficient Inhibitor of *Porphyromonas gingivalis* Induced by *Escherichia Coli* LPS. *Toxins* 2014, 6, 1663–1674. [CrossRef] [PubMed]

137. Yang, H.-N.; Lee, E.-H.; Kim, H.-M. Spirulina Platensis Inhibits Anaphylactic Reaction. *Life Sci.* 1997, 61, 1237–1244. [CrossRef]

138. Appel, K.; Munoz, E.; Navarrete, C.; Cruz-Teno, C.; Biller, A.; Thiemann, E. Immuno¬modulatory and Inhibitory Effect of Immunina®, and Immunologes® in the IgE Mediated Activation of RBL-2H3 Cells. A New Role in Allergic Inflammatory Responses. *Plants* 2018, 7, 13. [CrossRef]

139. Rod-in, W.; Monmai, C.; Lee, S.; Jung, S.-K.; You, S.; Park, W.J. Anti-Inflammatory Effects of Lipids Extracted from *Arctoscutus japonicus* Eggs on LPS-Stimulated RAW264.7 Cells. *Mar. Drugs* 2019, 17, 580. [CrossRef]

140. Li, Y.; Lee, S.-H.; Lee, Q.-T.; Kim, M.-M.; Kim, S.-K. Anti-Allergic Effects of Phlorotannins on Histamine Release via Binding Inhibition between IgE and FcεRI. *J. Agric. Food Chem.* 2008, 56, 12073–12080. [CrossRef]

141. Niu, S.; Liu, Q.; Xia, J.-M.; Xie, C.-L.; Luo, Z.-H.; Shao, Z.; Liu, G.; Yang, X.-W. Polyketides from the Deep-Sea-Derived Fungus *Graphostroma* Sp. MCCC 3A00421 Showed Potent Antifood Allergic Activities. *J. Agric. Food Chem.* 2018, 66, 1369–1376. [CrossRef]

142. Gao, Y.-Y.; Liu, Q.-M.; Liu, B.; Xie, C.-L.; Cao, M.-J.; Yang, X.-W.; Liu, G.-M. Inhibitory Activities of Compounds from the Marine Actinomycete *williamsia* Sp. MCCC 1A11233 Variant on IgE-Mediated Mast Cells and Passive Cutaneous Anaphylaxis. *J. Agric. Food Chem.* 2017, 65, 10749–10756. [CrossRef]

143. Lee, D.-I.; Park, M.-K.; Kang, S.A.; Choi, J.-H.; Kang, S.-J.; Lee, J.-Y.; Yu, H.S. Preventive Intra Oral Treatment of Sea Cucumber Ameliorate OVA-Induced Airway Inflammation. *Am. J. Chin. Med.* 2016, 44, 1663–1674. [CrossRef]

144. Onodera, K.; Konishi, Y.; Taguchi, T.; Kiyoto, S.; Tominaiga, A. Peridinin from the Marine Symbiotic Dinoflagellate, *Symbiodinium* Sp., Regulates Eosinophilia in Mice. *Mar. Drugs* 2014, 12, 1773–1787. [CrossRef]